EA033197B1 - Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b - Google Patents

Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b

Info

Publication number
EA033197B1
EA033197B1 EA201890245A EA201890245A EA033197B1 EA 033197 B1 EA033197 B1 EA 033197B1 EA 201890245 A EA201890245 A EA 201890245A EA 201890245 A EA201890245 A EA 201890245A EA 033197 B1 EA033197 B1 EA 033197B1
Authority
EA
Eurasian Patent Office
Prior art keywords
azaindoles
substituted
receptor modulators
nr2b
glun2b receptor
Prior art date
Application number
EA201890245A
Other languages
English (en)
Russian (ru)
Other versions
EA201890245A1 (ru
Inventor
Криста К. Кровиан
Майкл А. Летавич
Джейсон К. Рех
Акинола Сойод-Джонсон
Джессика Л. Уолл
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201890245A1 publication Critical patent/EA201890245A1/ru
Publication of EA033197B1 publication Critical patent/EA033197B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
EA201890245A 2015-07-09 2016-07-07 Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b EA033197B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190416P 2015-07-09 2015-07-09
PCT/US2016/041339 WO2017007938A1 (en) 2015-07-09 2016-07-07 Substituted 4-azaindoles and their use as glun2b receptor modulators

Publications (2)

Publication Number Publication Date
EA201890245A1 EA201890245A1 (ru) 2018-06-29
EA033197B1 true EA033197B1 (ru) 2019-09-30

Family

ID=56497884

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890245A EA033197B1 (ru) 2015-07-09 2016-07-07 Замещенные 4-азаиндолы и их применение в качестве модуляторов рецептора glun2b

Country Status (25)

Country Link
US (2) US9963447B2 (enExample)
EP (1) EP3319963B1 (enExample)
JP (2) JP6964576B2 (enExample)
KR (1) KR20180026760A (enExample)
CN (1) CN108026094B (enExample)
AU (1) AU2016291158B2 (enExample)
BR (1) BR112018000468A2 (enExample)
CA (1) CA2991765C (enExample)
CY (1) CY1123007T1 (enExample)
DK (1) DK3319963T3 (enExample)
EA (1) EA033197B1 (enExample)
ES (1) ES2781867T3 (enExample)
HR (1) HRP20200410T1 (enExample)
HU (1) HUE047460T2 (enExample)
IL (1) IL256758A (enExample)
LT (1) LT3319963T (enExample)
MA (1) MA42397B1 (enExample)
MD (1) MD3319963T2 (enExample)
MX (1) MX2018000352A (enExample)
PL (1) PL3319963T3 (enExample)
PT (1) PT3319963T (enExample)
SI (1) SI3319963T1 (enExample)
SM (1) SMT202000134T1 (enExample)
WO (1) WO2017007938A1 (enExample)
ZA (1) ZA201800827B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
PT3180315T (pt) 2014-08-15 2020-05-27 Janssen Pharmaceuticals Inc Pirazoles
MX2018000352A (es) 2015-07-09 2018-08-15 Janssen Pharmaceutica Nv 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
EP3774732A4 (en) * 2018-04-04 2022-02-09 Janssen Pharmaceutica NV PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
US20220324860A1 (en) * 2019-06-14 2022-10-13 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
EP3983413A1 (en) 2019-06-14 2022-04-20 Janssen Pharmaceutica NV Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators
AU2020290772A1 (en) 2019-06-14 2022-01-06 Janssen Pharmaceutica Nv Pyrazine carbamates and their use as GluN2B receptor modulators
JP7667097B2 (ja) 2019-06-14 2025-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用
SG11202112407PA (en) * 2019-06-14 2021-12-30 Janssen Pharmaceutica Nv Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators
AU2020291188A1 (en) * 2019-06-14 2022-01-20 Janssen Pharmaceutica Nv Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators
BR112021025132A2 (pt) 2019-06-14 2022-01-25 Janssen Pharmaceutica Nv Carbamatos de piridina e seu uso como moduladores do receptor glun2b
CN114621125B (zh) * 2020-12-14 2024-07-09 中国科学技术大学 Nlrp3炎症小体抑制剂及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082868A1 (en) * 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US20070275965A1 (en) * 2006-03-30 2007-11-29 Chemocentryx, Inc. CXCR4 modulators
US20080300239A1 (en) * 2007-05-18 2008-12-04 Adams Nicholas D Quinoline derivatives as pi3 kinase inhibitors
WO2010043396A1 (en) * 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005214375A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Triazole compounds and their use as metabotropic glutamate receptor antagonists
US20060183758A1 (en) * 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
KR20100017372A (ko) 2007-05-25 2010-02-16 애보트 게엠베하 운트 콤파니 카게 향대사성 글루타메이트 수용체 2（ｍｇｌｕ2 수용체）의 포지티브 조절자로서의 헤테로사이클릭 화합물
US20100325949A1 (en) 2007-07-03 2010-12-30 Edward Scott Carlson Support apparatus for climbing plants
WO2009028543A1 (ja) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited 置換ピラゾール誘導体
WO2009058261A1 (en) 2007-10-31 2009-05-07 Merck & Co., Inc. Modulation of sleep with nr2b receptor antagonists
US20110053951A1 (en) 2008-03-27 2011-03-03 Evotec Neurosciences Gmbh Methods for treating disorders using nmda nr2b-subtype selective antagonist
DK2308877T3 (da) 2008-08-05 2014-04-22 Daiichi Sankyo Co Ltd Imidazopyridin-2-on-derivater
CN102264743B (zh) 2008-11-25 2015-02-11 罗彻斯特大学 Mlk抑制剂及其使用方法
TWI625121B (zh) * 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
WO2013130855A1 (en) 2012-03-02 2013-09-06 Takeda Pharmaceutical Company Limited Indazole derivatives
TW201444820A (zh) * 2013-03-13 2014-12-01 Abbvie Inc 吡啶ｃｄｋ９激酶抑制劑
CN105073747B (zh) * 2013-03-15 2017-06-06 普莱希科公司 杂环化合物及其应用
CN103626767A (zh) * 2013-12-04 2014-03-12 上海药明康德新药开发有限公司 区域选择性的氮杂吲哚及其合成方法
PT3180315T (pt) 2014-08-15 2020-05-27 Janssen Pharmaceuticals Inc Pirazoles
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors
MX2018000352A (es) 2015-07-09 2018-08-15 Janssen Pharmaceutica Nv 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
KR20180108822A (ko) 2016-02-10 2018-10-04 얀센 파마슈티카 엔.브이. Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082868A1 (en) * 2002-03-28 2003-10-09 Eisai Co., Ltd. 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
US20070275965A1 (en) * 2006-03-30 2007-11-29 Chemocentryx, Inc. CXCR4 modulators
US20080300239A1 (en) * 2007-05-18 2008-12-04 Adams Nicholas D Quinoline derivatives as pi3 kinase inhibitors
WO2010043396A1 (en) * 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2014124651A1 (en) * 2013-02-15 2014-08-21 Københavns Universitet Pyrrolidine-2-carboxylic acid derivatives as iglur antagonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BUONARATI M H, TURTELTAUB K W, SHEN N H, FELTON J S: "Role of sulfation and acetylation in the activation of 2-hydroxyamino-1-methyl-6-phenyl-imidazo[4,5-b]pyridine to intermeidates which bind DNA", MUTATION RESEARCH LETTERS, ELSEVIER, NL, vol. 245, no. 3, 1 November 1990 (1990-11-01), NL, pages 185 - 190, XP002760909, ISSN: 0165-7992, DOI: 10.1016/0165-7992(90)90048-O *

Also Published As

Publication number Publication date
MX2018000352A (es) 2018-08-15
IL256758A (en) 2018-03-29
MD3319963T2 (ro) 2020-05-31
ES2781867T3 (es) 2020-09-08
EP3319963A1 (en) 2018-05-16
EA201890245A1 (ru) 2018-06-29
US10377753B2 (en) 2019-08-13
HRP20200410T1 (hr) 2020-08-21
JP7369743B2 (ja) 2023-10-26
BR112018000468A2 (pt) 2018-09-18
PL3319963T3 (pl) 2020-06-01
US9963447B2 (en) 2018-05-08
JP2018520170A (ja) 2018-07-26
AU2016291158B2 (en) 2020-04-30
CY1123007T1 (el) 2021-10-29
AU2016291158A1 (en) 2018-02-01
SI3319963T1 (sl) 2020-02-28
MA42397B1 (fr) 2020-02-28
ZA201800827B (en) 2019-09-25
CA2991765A1 (en) 2017-01-12
PT3319963T (pt) 2020-04-09
HK1255160A1 (en) 2019-08-09
CA2991765C (en) 2023-10-03
DK3319963T3 (da) 2020-02-03
CN108026094A (zh) 2018-05-11
CN108026094B (zh) 2021-02-09
US20180208595A1 (en) 2018-07-26
US20170008890A1 (en) 2017-01-12
LT3319963T (lt) 2020-03-25
KR20180026760A (ko) 2018-03-13
WO2017007938A1 (en) 2017-01-12
SMT202000134T1 (it) 2020-05-08
HUE047460T2 (hu) 2020-04-28
JP2021193099A (ja) 2021-12-23
EP3319963B1 (en) 2020-01-08
JP6964576B2 (ja) 2021-11-10

Similar Documents

Publication Publication Date Title
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
NZ737399A (en) Ccr2 modulators
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
PH12016501966A1 (en) Compounds and compositions as toll-like receptor 7 agonists
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2018006223A (es) Moduladores de ror-gamma.
UA122868C2 (uk) Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
EA024842B9 (ru) Соединения в качестве модуляторов протеинкиназы pi3k
MX2021015503A (es) Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
CR20210580A (es) Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
MX2016008898A (es) Antagonistas selectivos de nr2b.
GEAP201814266A (en) Pyrazines modulators of gpr6
GEP20186908B (en) P-substituted asymmetric ureas and medical uses thereof
MX381643B (es) Compuestos heteroarilo bicíclicos sustituidos como agonistas rxr.
PH12016501764B1 (en) Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016011900A (es) Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU